Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 12/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132648 | 0.83 | METAP2 (0.42) | METAP2DRD1TGFBR1PIM1 | |
| SCHEMBL15345023 | 0.75 | TRPA1 (0.48) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL15344157 | 0.72 | GSK3B (0.57) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL15344997 | 0.71 | CCR1 (0.46) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL31219877 | 0.70 | DRD1 (0.38) | DRD1TGFBR1 | |
| SCHEMBL25175308 | 0.70 | PIK3CA (0.43) | METAP2DRD1TGFBR1IDO1 | |
| SCHEMBL12657556 | 0.69 | CCR1 (0.61) | CCR1CCR5CCR8METAP2CYP2A6 | |
| SCHEMBL25171713 | 0.69 | MAP4K4 (0.42) | METAP2DRD1 | |
| SCHEMBL8404436 | 0.68 | IDO1 (0.46) | METAP2IDO1 | |
| SCHEMBL15756768 | 0.68 | NUDT1 (0.55) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CCR1 106/4885CCR5 3/4885CCR8 125/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CCR1 106/4885CCR5 3/4885CCR8 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.